article Open AccessTop 1% cited
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Epilepsia · 2015 · Vol. 56(8) · pp. 1246–1251
Alexandra L. Geffrey(Massachusetts General Hospital)Sarah F. Pollack(Massachusetts General Hospital)Patricia L. Bruno(Massachusetts General Hospital)Elizabeth A. Thiele✉(Massachusetts General Hospital)
Abstract
Monitoring of CLB and nCLB levels is necessary for clinical care of patients concomitantly on CLB and CBD. Nonetheless, CBD is a safe and effective treatment of refractory epilepsy in patients receiving CLB treatment.
Cannabis and Cannabinoid ResearchEpilepsy research and treatmentDrug Transport and Resistance MechanismsClobazamCannabidiolMedicineEpilepsyConcomitantLennox–Gastaut syndromeRefractory (planetary science)Internal medicineAdverse effectPharmacology
MeSH terms
ClobazamAdolescentBenzodiazepinesCannabidiolChildChild, PreschoolCytochrome P-450 Enzyme SystemDrug InteractionsEpilepsyFemaleHumansMaleYoung Adult
Funding
- Massachusetts General Hospital
- GW Pharmaceuticals
- H. Lundbeck A/S
- U.S. Food and Drug Administration
Citations
478
FWCI
34.89
field-weighted impact
References
24
Percentile
100%
vs. same field & year
Citations per year
Cited by
Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
Journal of Clinical Medicine · 2019 · 276 citations
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Frontiers in Pharmacology · 2018 · 526 citations
Mechanisms of action of currently used antiseizure drugs
Neuropharmacology · 2020 · 463 citations
The pharmacokinetics and the pharmacodynamics of cannabinoids
British Journal of Clinical Pharmacology · 2018 · 671 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.